The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
100
Mean Eosinophil Count
Time frame: Week 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Mayo Clinic - Arizona
Scottsdale, Arizona, United States
Desert Sun Clinical Research, LLC
Tucson, Arizona, United States
Alliance Clinical Research
Oceanside, California, United States
Precision Research Institute, LLC
San Diego, California, United States
University of Colorado School of Medicine
Aurora, Colorado, United States
Connecticut Clinical Research Foundation
Bristol, Connecticut, United States
University of Florida
Gainesville, Florida, United States
Borland-Groover Clinic
Jacksonville, Florida, United States
Children's Center for Digestive Healthcare
Atlanta, Georgia, United States
Grand Teton Research Group
Idaho Falls, Idaho, United States
...and 20 more locations